{"title":"[Advances on treatment of pediatric acute lymphoblastic leukemia with blinatumomab].","authors":"D. Wang, C. Zhao, X. J. Xu","doi":"10.3760/cma.j.cn112140-20231116-00375","DOIUrl":null,"url":null,"abstract":"\n 贝林妥欧单抗是一种同时靶向CD3和CD19的双特异性抗体，能激活内源性T细胞杀伤B系肿瘤细胞。自2014年美国食品药品监督管理局批准用于治疗复发难治性急性淋巴细胞白血病（ALL）以来，临床应用广泛，应用的指征不断前移，疗效和安全性均较好。在儿童白血病领域，除复发难治性ALL外，目前已经用于微小残留病阳性ALL的治疗以及高危ALL的一线治疗，同时也用于化疗不耐受患儿的治疗，并可桥接造血干细胞移植。本文就贝林妥欧单抗在儿童ALL治疗方面的临床研究进展进行综述。.\n","PeriodicalId":23998,"journal":{"name":"Zhonghua er ke za zhi = Chinese journal of pediatrics","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Zhonghua er ke za zhi = Chinese journal of pediatrics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3760/cma.j.cn112140-20231116-00375","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
